NCT00600496View on ClinicalTrials.gov

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 14, 2007

Primary Completion Date

August 20, 2010

Study Completion Date

December 31, 2025

Conditions
Breast CancerBreast NeoplasmsColon CancerColonic CancerColon NeoplasmsLung CancerMelanomaKidney Cancer
Interventions
DRUG

AZD6244

twice daily oral dose

DRUG

Dacarbazine

intravenous infusion

DRUG

Erlotinib

daily oral dose

DRUG

Docetaxel

intravenous infusion

DRUG

Temsirolimus

intravenous infusion

Trial Locations (4)

19111

Research Site, Philadelphia

37203

Research Site, Nashville

48201

Research Site, Detroit

77030

Research Site, Houston

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY